NCT05223205

Brief Summary

State of the art treatment for idiopathic macular holes consists of pars plana vitrectomy, internal limiting membrane staining with a blue colouring dye, internal limiting membrane peeling and filling of the vitrectomized space with a specific tamponade such as air and SF6. Air and SF6 have previously shown similar closure rates, although there was a trend towards lower closure rates in large diameter IMH (Idiopathic Macular Holes) using air. IMH with diameters \< 600 μm are currently believed to have similar closure rates with air and SF6. The investigators want to assess possible effects of the used tamponade (air or SF6) on closure rates and perfusion parameters represented by OCTA (Optical coherence tomography angiography). IMH eyes with a minimum diameter \> 600 μm will be excluded. Two idiopathic macular hole patient groups will therefore be formed: The first group (group 1) will receive air after vitrectomy and membrane peeling, the second group (group 2) will receive 10% SF6 (and 90% air) after vitrectomy and membrane peeling. After recruitment, patients will therefore be electronically randomized to one of the two groups. The groups will then be compared by the means of OCT (Optical coherence tomography) and OCTA. Note: The trial was registered retrospectively on Clinicaltrials.gov after start of recruitment.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jul 2020

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 6, 2020

Completed
1.6 years until next milestone

First Submitted

Initial submission to the registry

January 24, 2022

Completed
10 days until next milestone

First Posted

Study publicly available on registry

February 3, 2022

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 6, 2023

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 6, 2023

Completed
Last Updated

September 13, 2023

Status Verified

September 1, 2023

Enrollment Period

2.6 years

First QC Date

January 24, 2022

Last Update Submit

September 12, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • Macular hole closure

    2 weeks

Secondary Outcomes (2)

  • Foveal avascular zone area

    3 months

  • Parafoveal vessel density

    3 months

Study Arms (2)

Air group

EXPERIMENTAL

Air tamponade after vitrectomy.

Procedure: Air

SF6 group

EXPERIMENTAL

10% SF6 tamponade after vitrectomy.

Procedure: 10% SF6 and 90% air

Interventions

AirPROCEDURE

Test if air is sufficient for macular hole closure.

Air group

Test if 10% SF6 and 90% air is sufficient for macular hole closure.

SF6 group

Eligibility Criteria

Age18 Years - 99 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patient must be able and willing to give informed consent.
  • Patient must be between 18 and 100 years of age.
  • Patient must not have any significant media opacity which interferes with the examination.
  • Patient must have an (stage 1-4) idiopathic macular hole requiring surgery.

You may not qualify if:

  • Unwilling or unable to provide informed consent
  • Under 18 or over 100 years of age
  • Significant media opacities
  • Systemic pathologies making an examination difficult or cumbersome to the patient
  • Primary and/or secondary epiretinal membranes (ERM), except incipient ERMs not affecting the foveal contour and not requiring surgery
  • Full-thickness idiopathic macular hole \> 600 μm in minimum diameter
  • Nonclosure
  • Lamellar holes not requiring surgery
  • Pseudo holes
  • Glaucoma
  • Diabetes
  • Anisometropia \> 2 diopters
  • High myopia (spherical equivalent \> 6 diopters and/or axial length \> 26 mm
  • Other retinal or ophthalmic pathologies except moderate cataract
  • OCTA scan signal strength \< 5
  • +2 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Ophthalmology

Graz, Styria, 8036, Austria

Location

MeSH Terms

Conditions

Retinal Perforations

Interventions

Air

Condition Hierarchy (Ancestors)

Retinal DiseasesEye Diseases

Intervention Hierarchy (Ancestors)

AtmosphereEnvironmentEcological and Environmental PhenomenaBiological PhenomenaMeteorological ConceptsEnvironment and Public Health

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 24, 2022

First Posted

February 3, 2022

Study Start

July 6, 2020

Primary Completion

February 6, 2023

Study Completion

June 6, 2023

Last Updated

September 13, 2023

Record last verified: 2023-09

Locations